Mark J. Foley - Sep 22, 2022 Form 4 Insider Report for Revance Therapeutics, Inc. (RVNC)

Role
CEO, Director
Signature
/s/ Dwight Moxie, Attorney-in-Fact
Stock symbol
RVNC
Transactions as of
Sep 22, 2022
Transactions value $
-$2,223,360
Form type
4
Date filed
3/9/2023, 08:45 PM
Previous filing
Jul 5, 2022
Next filing
Oct 14, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RVNC Common Stock Award $0 +176K +24.46% $0.00 894K Sep 22, 2022 Direct F1
transaction RVNC Common Stock Sale -$2.22M -70.4K -7.88% $31.59 823K Mar 9, 2023 Direct F2
holding RVNC Common Stock 111K Sep 22, 2022 See footnote F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents settlement of a performance-based restricted stock unit ("PSU") granted on February 2, 2022. On September 22, 2022, the Company's Compensation Committee certified 100% of the PSUs eligible to vest based on i) the achievement of the U.S. Food and Drug Administration's ("FDA") approval of the Issuer's biologics license application (BLA) for DAXXIFY(R) for the improvement of glabellar lines ("FDA Approval") and ii) subject to the Reporting Person remaining in continuous service through the six-month anniversary following the date of the FDA Approval which six-month anniversary was March 7, 2023.
F2 Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of PSUs. This sale is mandated by the Issuer's sell to cover agreement that requires the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.
F3 These shares are held by the Mark and Dana Foley, Trustees, Foley Family Trust U/A DTD 4/10/2002.